由主要保险公司批准的ARS Pharma's neffy nasal喷雾剂, 现可供20M病人使用, ARS Pharma's neffy® nasal spray, approved by major insurers, now accessible to 20M patients, launches free school program.

在Cigna保健、Navitus保健系统和OptumRx的配方中增加了ARS制药公司的肾上腺素鼻涕喷雾剂,使大约2 000万有严重过敏反应的病人更容易获得这种喷雾剂。 ARS Pharmaceuticals' neffy® epinephrine nasal spray has been added to the formularies of Cigna Healthcare, Navitus Health Systems, and OptumRx, enhancing access for about 20 million patients with severe allergic reactions. 这使涉及该药物的总共30个配方。 This brings the total to 30 formularies covering the drug. ARS Pharma还启动了neffin学校方案,向美国各地的K-12学校免费提供鼻涕喷雾剂,帮助66磅以上的儿童快速治疗过敏反应。 ARS Pharma also launched the neffyinSchools program, offering free nasal sprays to K-12 schools across the US, aiding in the quick treatment of allergic reactions in children over 66 lbs.